ErbB2 receptor immunoreactivity in prostate cancer: Relationship to the androgen receptor, disease severity at diagnosis and disease outcome

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Hammarsten, Peter ^a   Winther, Johanna ^a   Rudolfsson, Stina H ^a   Häggström, Jenny ^b   Karalija, Amar ^a   Egevad, Lars ^c   Granfors, Torvald ^d   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN KINASE B; ANDROGEN;

ADULT; ANDROGEN BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; ERBB2 GENE; GENE EXPRESSION REGULATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TISSUE MICROARRAY; ANIMAL; CASTRATION; DISEASE COURSE; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANDROGENS; ANIMALS; CASTRATION; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 84933059923     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105063     Document Type: Article

References (35)

1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-37.
2. Eccles SA (2011) The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 55: 685-96.
3. Sendur MAN, Aksoy S, Altundag K (2012) Pertuzumab in HER2-positive breast cancer. Curr Med Res Opin 28: 1709-16.
4. Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormoneindependent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-5.
5. Kerbel RS (2003) Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2: S134-S139.
6. Marengo SR, Sikes RA, Anezinis P, Chang S-M, Chung LWK (1997) Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Mol Carcinog 19: 165-75.
7. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D (2002) Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62: 5485-8.
8. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, et al. (2006) Androgen dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66: 5723-5728.
9. Myers RB, Oelschlager D, Manne U, Coan PN, Weiss H, et al. (1999) Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. Int J Cancer 82: 424-9.
10. Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, et al. (2010) Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 16: 1553-1560.
11. Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, et al. (2010) Her-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis. J Urol 184: 842-850.
12. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P (2002) Prognostic value of the Gleason score in prostate cancer. BJU International 89: 538-42.
13. Josefsson A, Wikstrom P, Egevad L, Granfors T, Karlberg L, et al. (2012) Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand J Urol Nephrol 46: 247-257.
14. Hammarsten P, Cipriano M, Josefsson A, Stattin P, Egevad L, et al. (2012) Phospho-Akt immunoreactivity in prostate cancer: Relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One 7: E47994.
15. Wikström P, Marusic J, Stattin P, Bergh A (2009) Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 69: 799-809.
16. Franck-Lissbrant I, Häggström S, Damber JE, Bergh A (1998) Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology. 139: 451-6.
17. Khimani AH, Mhashilkar AM, Mikulskis A, O'Malley M, Liao J, et al. (2005) Housekeeping genes in cancer: Normalization of array data. Biotechniques 38: 739-745.
18. Byun J, Logothetis CJ, Gorlov IP (2009) Housekeeping genes in prostate tumorigenesis. Int J Cancer 125: 2603-8.
19. The R Project for Statistical Computing website. Available: http:|//www.rproject.org. Accessed 2014 Aug 16.
20. Lehmann R (1977) General derivation of partial and multiple rank correlation coefficients. Biom J 19: 229-236.
21. Ricciardelli C, Jackson MW, Choong CS, Stahl J, Marshall VR, et al. (2008) Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 68: 830-838.
22. Perkins NJ, Schisterman EF (2006) The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 163: 670-5.
23. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, et al. (2001) HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7: 2643-2647.
24. Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, et al. (2008) Longterm assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate 68: 1806-1815.
25. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, et al. (1997) Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 3: 21-30.
26. Mimeault M, Batra SK (2006) Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27: 1-22.
27. Ahmad I, Patel R, Singh LB, Nixon C, Seywright M, et al. (2011) HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A 108: 16392-16397.
28. Le Page C, Koumakpayi IH, Péant B, Delvoye N, Saad F, et al. (2012) ErbB2/Her-2 regulates the expression of Akt2 in prostate cancer cells. Prostate 72: 777- 88.
29. Gregory CW, Whang YE, McCall W, Fei X, Liu Y, et al. (2005) Heregulininduced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11: 1704-1712.
30. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB (2009) The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 94: 907-13.
31. Jathal MKm Chen L, Mudryj M, Ghosh PM (2001) Targeting ErbB3: The New RTK(id) on the prostate cancer block. Immunol Endocr Metab Agents Med Chem 11: 131-49.
32. Fan J, Upadhye S, Worster A (2006) Understanding receiver operating characteristic (ROC) curves. CJEM 8: 19-20.
33. Hus F-N, Yang M-S, Lin E, Tseng C-F, Lin H (2011) The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells. Am J Physiol Endocrinol Metab 300: E902-E8.
34. Hammarsten P, Rudolfsson SH, Henriksson R, Wikstrom P, Bergh A (2007) Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats. Prostate 67: 573-581.
35. Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikstrom P, et al. (2010) Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 16: 1245-1255.